Andrew Sohn, MD
Rheumatology · Everett, WANPI 1215977897
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.3% of the total across 210 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 33.5% of the total. Reporting peaked in 2019 at $2,053 and has fallen 84.4% since, to $321 in 2025.
Across 210 payments — averaging $16.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Amgen$538
- Johnson & Johnson$264
- Novartis$199
- E.r. Squibb & Sons, L.L.C.$171
- Bristol Myers Squibb$158
- plus $908 from 14 others
What the payments were for
- Food & beverage$3,27397%
- Education$923%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 69 | $1,127 |
| Amgen(2 entities) | 28 | $538 |
| Johnson & Johnson(2 entities) | 12 | $264 |
| Novartis | 27 | $199 |
| E.r. Squibb & Sons, L.L.C. | 13 | $171 |
| Bristol Myers Squibb | 11 | $158 |
| GSK | 8 | $143 |
| Mallinckrodt Enterprises LLC | 9 | $143 |
| Pfizer | 8 | $134 |
| Lilly USA, LLC | 5 | $97 |
| Sobi, Inc | 3 | $81 |
| UCB, Inc. | 3 | $58 |
| AstraZeneca | 2 | $52 |
| Genentech USA, Inc. | 3 | $47 |
| Mallinckrodt Hospital Products Inc. | 3 | $46 |
| Janssen Scientific Affairs, LLC | 1 | $39 |
| Regeneron Healthcare Solutions, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $15 |
| Medexus Pharma, Inc. | 1 | $14 |
| Hikma Pharmaceuticals USA | 1 | $13 |
How this compares
$3,365 in reported general payments places this provider in the 70th percentile of 157 rheumatology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 70 | $600,715 |
| Humira(Cf) PenAdalimumab | 41 | $337,445 |
| RinvoqUpadacitinib | 47 | $308,270 |
| EnbrelEtanercept | 23 | $261,399 |
| Orencia ClickjectAbatacept | 22 | $124,409 |
| Actemra ActpenTocilizumab | 30 | $106,713 |
| SimponiGolimumab | 17 | $104,943 |
| Xeljanz XrTofacitinib Citrate | 11 | $73,994 |
| ForteoTeriparatide | 11 | $54,928 |
| ProliaDenosumab | 29 | $51,170 |
| Hydroxychloroquine Sulfate | 465 | $17,080 |
| Amjevita(Cf) AutoinjectorAdalimumab-Atto | 13 | $13,862 |
| MethotrexateMethotrexate Sodium | 580 | $9,872 |
| Leflunomide | 139 | $5,425 |
| Sulfasalazine | 161 | $4,693 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel, Prolia | $538 | $312,56952 claims |
| AbbVieRinvoq | $1,127 | $308,27047 claims |
| Johnson & JohnsonSimponi | $264 | $104,94317 claims |
| Lilly USA, LLCForteo | $97 | $54,92811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 157 rheumatology providers in Washington.
Other rheumatology in Everett
- Stanford PengSeattle$3.5M
- Jeff PetersonBothell$2.3M
- Philip MeaseSeattle$2.1M
- Robert EttlingerTacoma$232K
- Richard JimenezBothell$155K
- Howard KenneySpokane$132K
- Arinola DadaBellevue$69K
- Verlene GauthierCovington$63K
- Jane BucknerSeattle$57K
- Andrew SolomonBothell$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.